Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EXO-ME/CFS exploratory safety study in post-COVID or post-vaccination ME/CFS
jRCTs031260616Recruiting
- Sponsor
- CES Descartes
- Start
- Oct 2026
- Countries
- 1
01
Overview
Open-label, single-arm trial of exosome-based investigational product in myalgic encephalomyelitis (ME), sponsored by CES Descartes. Primary endpoint: Incidence of adverse events through 2 weeks after final administration. Started Oct 2026; status: recruiting.
02
Drugs
exosome-based investigational product
03
Conditions
myalgic encephalomyelitis (ME)
Beyond the preview
Go deeper on jRCTs031260616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031260616.